Navigation Links
SCOLR Pharma, Inc. Announces Final Closing of Private Placement
Date:6/30/2011

BOTHELL, Wash., June 30, 2011 /PRNewswire/ -- SCOLR Pharma, Inc. (OTC: SCLR) today announced that it has closed the second and final tranche of its previously-announced private placement of its 8% Senior Secured Convertible Debentures due 2013 (the "Debentures").  The Company raised a total of $1,190,200 in the offering.  The Company intends to use the net proceeds for working capital and other general corporate purposes.

Stephen J. Turner, President and Chief Executive Officer, said: "The completion of this offering will allow us to continue to focus on the development of our nutritional business and on our efforts to secure licensing or partnership support for our pharmaceutical products.  We are making good progress in placing our nutritional products on retail shelves and this capital will enable us to be even more aggressive in those efforts."

This second tranche consisted of the sale of an additional $189,000 principal amount of Debentures.  The Debentures, together with accrued and unpaid interest, are convertible at the option of the holders into shares of the Company's common stock at a conversion price equal to $0.05 per share of common stock.  Beginning after the date that is six months from the issuance of the Debentures, the Company may cause mandatory conversion of the Debentures following the continuance for 30 consecutive days of certain conditions, including maintenance of a volume weighted average trading price on each day within such 30 day period of $0.25 per share of common stock.  The Debentures bear interest of 8% per annum, compounded quarterly, and are secured by all the Company's assets.  The Company may, at any time and from time to time, upon 10 days prior notice to the holders, pay in cash all or a portion of the accrued and unpaid interest on the Debentures, or may cause conversion of such accrued and unpaid interest in connection with any mandatory conversion of the Debentures.


'/>"/>
SOURCE SCOLR Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
2. SCOLR Pharma, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
3. FDA Issues Complete Response Letter to SCOLR Pharmas Abbreviated New Drug Application for CDT(R) 12-Hour Pseudoephedrine
4. SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results
5. SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results
6. SCOLR Pharma, Inc. Announces Initial Closing of Private Placement
7. Zosano Pharma, Inc. Announces Appointment of Gail Schulze as Chair and CEO
8. Thomas K. Equels Elected to Hemispherx BioPharma, Inc. Board of Directors
9. Neurobiological Technologies Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009
10. Houlihan Smith Arranges Non-Control Equity Investment Into Sottera, Inc., dba NJOY, by Miri Pharma, Inc.
11. Sinobiopharma, Inc. Appoints New Director of Marketing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... Delcath Systems, Inc. (NASDAQ: DCTH ... focused on oncology with an emphasis on the ... that results of a large, European single-center experience ... hepatic metastases with the Delcath Hepatic CHEMOSAT ® ... abstract at the American Society of Clinical Oncology ...
(Date:5/29/2015)... 29, 2015  Caris Life Sciences® today announced ... which researchers utilized Caris Molecular Intelligence®, the company,s ... therapeutic targets in patients with colorectal and pancreatic ... cell death protein 1 (PD-1) and its ligand, ... the 2015 American Society of Clinical Oncology Annual ...
(Date:5/29/2015)... , May 28, 2015 Research ... addition of Jain PharmaBiotech,s new report "Cytogenetics ... offering. This report deals with cytogenetics ... use mainly to describe the chromosome structure and ... of molecular biology, it is also referred to ...
(Date:5/29/2015)... MILWAUKEE, WISCONSIN (PRWEB) May 29, 2015 ... oncolytic virus talimogene laherparepvec and its ability to reduce ... the treatment have been published in the Journal of ... 436 patients with stages IIIB, IIIC and IV melanoma, ... goal of the study was to evaluate the safety ...
Breaking Biology Technology:Positive Data With Delcath's CHEMOSAT Highlighted At ASCO 2015 2Positive Data With Delcath's CHEMOSAT Highlighted At ASCO 2015 3Positive Data With Delcath's CHEMOSAT Highlighted At ASCO 2015 4Positive Data With Delcath's CHEMOSAT Highlighted At ASCO 2015 5Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 2Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 3Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 4Global Cytogenetics Market Report 2015-2024 - Technologies, Markets and Companies 2Global Cytogenetics Market Report 2015-2024 - Technologies, Markets and Companies 3Study Published in Journal of Clinical Oncology Reports Talimogene Laherparepvec Improvesdurable Responses in Patients with Advanced Melanoma 2
... , SEATTLE, June 30 Cell Therapeutics, Inc. ("CTI") (Nasdaq and ... Russell 3000(R), Russell 2000(R) and Russell Global(R) Indexes posted by Russell ... Russell Investments reconstitutes its family of U.S. and global equity ... reconstitution of Russell,s U.S. indexes captures the 4,000 largest U.S. stocks ...
... Centocor Ortho Biotech Inc. announced today that a federal ... Laboratories in a patent infringement suit. , , "We ... in the patent litigation case against Abbott," said Kim Taylor, ... relates to the company,s anti-TNF class of arthritis treatments, and ...
... LYNBROOK, N.Y., June 29 BioSpecifics Technologies Corp. (Nasdaq: ... collagenase-based products, announced today that it was added to the ... of the U.S. markets on June 29, 2009. The Russell ... to be a comprehensive representation of the investable U.S. equity ...
Cached Biology Technology:Cell Therapeutics Added to Russell 3000(R), Russell 2000(R) and Russell Global(R) Indexes 2Cell Therapeutics Added to Russell 3000(R), Russell 2000(R) and Russell Global(R) Indexes 3Centocor Ortho Biotech Inc. Awarded $1.67 Billion Patent Jury Verdict from Abbott Laboratories 2BioSpecifics Technologies Corp. Added to Russell 3000 and Russell 2000 Indexes 2
(Date:5/27/2015)...   Codonics (codonics.com), a global ... documentation solutions and Omnicell  (omnicell.com), a ... is pleased to announce their state of ... System® (SLS), an award-winning FDA class 2 ... Anesthesia Workstation, helps prevent medication errors, streamlines ...
(Date:5/25/2015)... 25, 2015  Australia,s market for wearable technologies is ... saw the advent of several trials and prototypes. The ... is expected to ignite interest in wearables as well ... Australia . This in turn will spur greater ... new partnerships amongst vendors and distributors. ...
(Date:5/22/2015)... , May 22, 2015 According ... by Solution (2D, 3D, Thermal, Emotion, Forensic), by Software (Middleware, ... (Government and Utilities, Consumer and Home) - Global Forecast ... grow from $2.77 Billion in 2015 to $6.19 Billion ... Browse 79 market data Tables and   43 ...
Breaking Biology News(10 mins):Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 3Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 4Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3
... New York, NYDecember 7, 2011Thanks to a new ... be able to diagnose in their offices non-periodic ... Non-periodic arrhythmias include atrial and ventricular fibrillation, which ... can in some cases be life-threatening. ...
... are moving to higher elevations because of climate change, but ... new study by Duke University researchers. The study, published ... finds that the birds aren,t migrating as rapidly as scientists ... The animals instead may be tracking changes in vegetation, which ...
... of physicians and scientists at Barrow Neurological Institute, in ... first-of-its-kind biography of Ukranian anatomist and histologist Vladimir Betz. ... Betz and a New Era of Neuroscience," appears in ... Brain . Among other contributions, Vladimir Alekseyevich Betz ...
Cached Biology News:New Columbia engineering technique diagnoses non-periodic arrhythmias in a single heartbeat 2Climate change driving tropical birds to higher elevations 2
... White walled plates enhance luminescent ... and fluorescence,• Not treated (or medium ... nature and binds biomolecules through passive ... immobilization of large molecules, such as ...
BD Falcon microtest assay plate. 1536 well 12l, black, flat-bottom PS. Polystyrene, nonsterile, no lid. (15/sp, 60/ca) Packaging: 15 / pack, 60 / case ...
... solution for all plate washing needs in both ... ,The PW 384 provides an excellent solution for ... Discovery (Assay development, Screening or Lead Optimization) and ... ,The PW 384 has set a standard for ...
... is a compact benchtop and stackable ... controller with a large display screen ... speed. Air circulation inside to evenly ... can be easily calibrated from the ...
Biology Products: